Sihuan Pharmaceutical, a Chinese manufacturer of cardio-cerebral vascular drugs, has pulled off another popular initial public offering in Hong Kong despite a fairly dear price, bucking an earlier trend of companies needing inexpensive valuations to be able to attract a decent amount of funds.
¬ Haymarket Media Limited. All rights reserved.
